Coherus Oncology (CHRS) Assets (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Assets data on file, last reported at $266.0 million in Q1 2026.

• For the quarter ending Q1 2026, Assets fell 28.31% year-over-year to $266.0 million; the trailing twelve-month figure through Mar 2026 stood at $266.0 million (down 28.31% YoY), and the FY2025 full-year result was $258.3 million, down 42.4% from the prior year.
• Assets advanced to $266.0 million in Q1 2026, from $258.3 million in the prior quarter.
• In the past five years, Assets ranged from a high of $763.5 million in Q1 2024 to a low of $258.3 million in Q4 2025.
• A 5-year average of $500.0 million and a median of $505.0 million in 2024 frame the typical range for Assets.
• Across the five-year window, Assets surged 89.74% in 2024 and tumbled 51.4% in 2025, its largest moves.
• Tracing CHRS's Assets over 5 years: stood at $480.8 million in 2022, then soared by 30.94% to $629.6 million in 2023, then fell by 28.76% to $448.5 million in 2024, then plunged by 42.4% to $258.3 million in 2025, then gained by 2.97% to $266.0 million in 2026.
• Business Quant data shows CHRS's Assets at $266.0 million in Q1 2026, $258.3 million in Q4 2025, and $516.5 million in Q3 2025.